Can you please explain the difference between health related benefits and harms and non heath related benefits and harms

Can you give an example of each and explain their relation to the concept?

A great deal of past and recent healthcare concern has centered on the errors made in patient care or overall healthcare of people. Many suggest that the legalities of healthcare attempt to balance the expectations of society for healthcare and the mistakes of caregivers with thousands of successful events of exceptional care each year. Yet many cases of errors in care also often go unnoticed or unreported simply because a patient or family member is reluctant to complain about their or their loved one's care for a variety of reasons. Why do you think patients are reluctant to complain about their care and what are some of the reasons for mistakes or errors in care? Discuss this in two different contexts: you as a patient, and your parent or child as a patient.

Who are the key players in a rolling budget and what are their roles?

You are working in the Emergency Department when EMS brings in a 3 year old struck by a drunk driver while riding his tricycle in the street. Despite all efforts by you and your trauma team, the child dies of his injuries. Discuss how you would speak with the family about the child's death - is there anyone you would involve - any type of referrals? This is the second child that has died in your department in 2 weeks. Discuss how you, as a nurse, would handle this additional stress.

Explain in your own words what you are to code when the first listed diagnosis is unconfirmed? Give an example coding scenario.

The Affordable Care Act (ACA) of 2010 has dramatically changed the U.S. health care system. Despite the beneficent intent of the reform, however, it has been suffering from many problems like the rise of insurance cost, etc. Discuss ethical challenges present in the ACA era from the market economic point of view

Do you believe that the ACA Reform is a move bringing our society one step closer to justice or fairness, or the opposite? Base your answers on the explanations you have provided in the questions above and expand.

Technology has certainly changed the way health care is practiced. Show some of the technological changes you have seen in the last five years, including both information and clinical technologies, and discuss what ethical issues the changes have created in a healthcare setting.

Mr. DM, a 79-year-old man who lives alone, is brought into A&E suffering from dehydration, which appears to be the result of prolonged (>24 hours) nausea and vomiting. He is shaking, confused, incoherent and unable to provide a lucid history. His basic laboratory values are: Na+ 152 mmol/L (137–145 mmol/L) K+ 3.1 mmol/L (3.6–5.0 mmol/L) Bicarbonate 29 mmol/L (22–30 mmol/L) Urea 7.3 mmol/L (2.5–7.5 mmol/L) Creatinine 115 micromol/L (62–133 micromol/L) White blood count 8.4 × 109 /L (4–11 × 109 /L) He has an intravenous cannula inserted and rehydration commenced with sodium chloride 0.9% w/v infusion. Mr. DM continues to retch and vomit. He is administered 10 mg metoclopramide by I.V. injection and promptly suffers an oculogyric crisis. This is reversed by the administration of I.V. Procyclidine. Twelve hours later Mr. DM is conscious and lucid but now has a pronounced tremor, characteristic of Parkinson’s disease. He reports he was initially diagnosed about a year ago by his GP. His GP has been prescribing Sinemet-110 (Co-careldopa) tablets, (the initial dose was titrated) but Mr. DM did not take any as the tremor did not really bother him until earlier this week. He decided to start taking the Sinemet but as the tremor was troublesome he started at the dose of 1 tablet T.D.S.

QUESTIONS:

1. Briefly outline the epidemiology, pathophysiology and clinical features of Parkinson’s disease.

2. Outline the pharmacological basis of the nausea and vomiting caused by the Sinemet.

3. Outline the pharmacological basis of the adverse effect, oculogyric crisis, Mr. DM suffered. '

4. Briefly discuss the alternative options that could have been considered for managing Mr. DM’s nausea and vomiting, with relative advantages and disadvantages.

5. Briefly outline the rationale for reducing the dosage interval rather than increasing the dosage.

6. The on/off syndrome and end-of-dose deterioration are both features of treated Parkinson’s disease. What are they, and are there any risk factors?

7. In addition to levodopa therapy, what other options are available to treat Parkinson’s disease and what is their place in therapy?

8. Mr. DM is concerned that he is likely to forget the five times daily dosage regimen and/or find it difficult to maintain a regular dosage interval. Is there anything you could do to help him?

What are two strategies you can use to monitor your own work to ensure the required standard of support is maintained?